The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO GI 2021 | LY3410738: a first-in-class covalent inhibitor of mutant IDH1 in CCA

Name: LY3410738: a first-in-class covalent inhibitor of mutant IDH1 in CCA
Uploaded: 2021-01-07T00:00:00Z
Duration: 1 min 52 s
Description: Rachna T. Shroff, MD, University of Arizona Cancer Center, Tucson, AZ, discusses an ongoing Phase I study evaluating LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma (CCA) and other advanced solid tumors. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Rachna T. Shroff • 7 Jan 2021

ASCO GI 2021

Bile Duct Cancer Gastrointestinal Cancer Cisplatin Gemcitabine Ivosidenib LY3410738

Rachna T. Shroff, MD, University of Arizona Cancer Center, Tucson, AZ, discusses an ongoing Phase I study evaluating LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma (CCA) and other advanced solid tumors. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).